Fetal growth disorders detection during first trimester gestation through comprehensive maternal circulating DNA profiling.

Journal: Human molecular genetics
Published Date: Jun 18, 2025

Abstract

BACKGROUND: Early diagnosis, close follow-up and timely delivery constitute the main elements for appropriate detection and management of Fetal Growth Disorders (FGD). We hypothesized that fetoplacental FGD-associated alterations can be detected in circulating DNA (cirDNA) samples isolated from maternal blood, as early as the first gestational trimester.

Authors

  • Rene Cortese
    Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65212, USA.
  • Kylie Cataldo
    Department of Gynecology, Obstetrics and Women's Health, University of Missouri, 1 Hospital Dr. Columbia, MO 65212, United States.
  • Justin Hummel
    Institute for Data Science and Informatics, University of Missouri, Columbia, 22 Heinkel Building, MO 65211 United States.
  • Gracie Smith
    Department of Gynecology, Obstetrics and Women's Health, University of Missouri, 1 Hospital Dr. Columbia, MO 65212, United States.
  • Madison Ortega
    Department of Gynecology, Obstetrics and Women's Health, University of Missouri, 1 Hospital Dr. Columbia, MO 65212, United States.
  • Madison Richey
    Department of Gynecology, Obstetrics and Women's Health, University of Missouri, 1 Hospital Dr. Columbia, MO 65212, United States.
  • Hung Winn
    Department of Gynecology, Obstetrics and Women's Health, University of Missouri, 1 Hospital Dr. Columbia, MO 65212, United States.
  • David Gozal
    Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States.
  • Jean Ricci Goodman
    Department of Gynecology, Obstetrics and Women's Health, University of Missouri, 1 Hospital Dr. Columbia, MO 65212, United States.

Keywords

External Resources

Popular Topics
Recent Journals